vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and Recon Technology, Ltd (RCON). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $12.2M, roughly 1.2× Recon Technology, Ltd). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -6.8%, a 81.9% gap on every dollar of revenue.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
Recon Instruments Inc. was a Canadian technology company that produced smartglasses and wearable displays marketed by the company as "heads-up displays" for sports. Recon's products delivered live activity metrics, GPS maps, and notifications directly to the user's eye. Recon's first heads-up display offering was released commercially in October 2010, roughly a year and a half before Google introduced Google Glass.
NEUP vs RCON — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.2M |
| Net Profit | $11.3M | $-832.7K |
| Gross Margin | — | 33.5% |
| Operating Margin | 79.8% | -14.6% |
| Net Margin | 75.1% | -6.8% |
| Revenue YoY | — | 111.0% |
| Net Profit YoY | — | 70.5% |
| EPS (diluted) | $6.55 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.2M | ||
| Q1 25 | $15.0M | — | ||
| Q4 24 | — | $5.8M | ||
| Q4 23 | — | $6.4M |
| Q4 25 | — | $-832.7K | ||
| Q1 25 | $11.3M | — | ||
| Q4 24 | — | $-2.8M | ||
| Q4 23 | — | $-3.2M |
| Q4 25 | — | 33.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 31.7% | ||
| Q4 23 | — | 26.7% |
| Q4 25 | — | -14.6% | ||
| Q1 25 | 79.8% | — | ||
| Q4 24 | — | -63.9% | ||
| Q4 23 | — | -50.4% |
| Q4 25 | — | -6.8% | ||
| Q1 25 | 75.1% | — | ||
| Q4 24 | — | -48.9% | ||
| Q4 23 | — | -49.8% |
| Q4 25 | — | $-0.09 | ||
| Q1 25 | $6.55 | — | ||
| Q4 24 | — | $-0.31 | ||
| Q4 23 | — | $-1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.0M | $66.4M |
| Total Assets | $30.7M | $77.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q1 25 | $17.0M | — | ||
| Q4 24 | — | $19.9M | ||
| Q4 23 | — | $36.0M |
| Q4 25 | — | $66.4M | ||
| Q1 25 | $26.0M | — | ||
| Q4 24 | — | $66.9M | ||
| Q4 23 | — | $60.0M |
| Q4 25 | — | $77.6M | ||
| Q1 25 | $30.7M | — | ||
| Q4 24 | — | $74.2M | ||
| Q4 23 | — | $68.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | $-1.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.9M | ||
| Q1 25 | $11.5M | — | ||
| Q4 24 | — | $-1.7M | ||
| Q4 23 | — | $-931.0K |
| Q4 25 | — | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
